We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Disease-specific expansion of CD29<sup>+</sup>IL-17RA<sup>+</sup> T effector cells possessing multiple signalling pathways in spondyloarthritis.
- Authors
Akiyama, Mitsuhiro; Yoshimoto, Keiko; Ishigaki, Sho; Suzuki, Katsuya; Takeuchi, Tsutomu; Kaneko, Yuko
- Abstract
Objectives T cells adhere to enthesis fibrocartilage via integrins and intrinsically require IL-17RA-mediated signals to maintain their effector function. We analysed CD29+IL-17RA+ T cells in inflamed lesions and peripheral blood in patients with SpA and investigated their association with disease activity and therapeutic response. Methods Transcriptome analysis of synovial fluid T cells from PsA was performed using publicly available bulk cell RNA sequencing data. Blood samples were obtained from healthy controls (n = 37), RA (n = 12), IgG4-related disease (IgG4-RD; n = 12), large vessel vasculitis (LVV; n = 12) and SpA (n = 28) and were analysed by flow cytometry. Results T cells in the inflamed joints of PsA showed CD29 and IL-17RA expression. CD29+IL-17RA+ T cells showed enriched CXCR3+CD45RA+ effector cells and activation of spleen tyrosine kinase (Syk), nuclear factor κB (NF-κB) and Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathways. The proportion of peripheral blood CD29+IL-17RA+ T cells was significantly increased in patients with SpA compared with patients with RA, IgG4-RD or LVV and in healthy controls. Based on the ASDAS-CRP scores, the proportion of CD29+IL-17RA+ T cells was positively correlated with disease activity in treatment-naïve patients with active SpA. Anti-IL-17 but not anti-TNF monoclonal antibodies reduced CD29+IL-17RA+ T cells. Conclusions CD29+IL-17RA+ T effector cells with enhanced Syk, NF-κB and JAK-STAT pathways were specifically increased in SpA and were correlated with disease activity, implicating a role of this newly identified T cell population in the pathogenesis. Anti-IL-17 monoclonal antibodies may be effective for patients by reducing this pathogenic T cell population.
- Subjects
ANKYLOSIS; CELLULAR signal transduction; SPONDYLOARTHROPATHIES
- Publication
Rheumatology, 2023, Vol 62, Issue 3, p1296
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/keac391